Mineralys Therapeutics, Inc. (MLYS)
25.29
-0.36
(-1.40%)
USD |
NASDAQ |
Aug 24, 16:00
25.29
0.00 (0.00%)
After-Hours: 20:00
Mineralys Therapeutics Enterprise Value : 1.702B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 1.702B |
| August 20, 2026 | 1.711B |
| August 19, 2026 | 1.817B |
| August 18, 2026 | 1.787B |
| August 17, 2026 | 1.738B |
| August 14, 2026 | 1.702B |
| August 13, 2026 | 1.741B |
| August 12, 2026 | 1.826B |
| August 11, 2026 | 1.851B |
| August 10, 2026 | 1.855B |
| August 07, 2026 | 1.853B |
| August 06, 2026 | 1.821B |
| August 05, 2026 | 1.808B |
| August 04, 2026 | 1.778B |
| August 03, 2026 | 1.714B |
| July 31, 2026 | 1.691B |
| July 30, 2026 | 1.750B |
| July 29, 2026 | 1.764B |
| July 28, 2026 | 1.817B |
| July 27, 2026 | 1.840B |
| July 24, 2026 | 1.796B |
| July 23, 2026 | 1.822B |
| July 22, 2026 | 1.823B |
| July 21, 2026 | 1.868B |
| July 20, 2026 | 1.796B |
| Date | Value |
|---|---|
| July 17, 2026 | 1.830B |
| July 16, 2026 | 1.829B |
| July 15, 2026 | 1.849B |
| July 14, 2026 | 1.846B |
| July 13, 2026 | 1.874B |
| July 10, 2026 | 1.944B |
| July 09, 2026 | 1.995B |
| July 08, 2026 | 2.122B |
| July 07, 2026 | 2.127B |
| July 06, 2026 | 2.009B |
| July 02, 2026 | 1.883B |
| July 01, 2026 | 1.812B |
| June 30, 2026 | 1.820B |
| June 29, 2026 | 1.570B |
| June 26, 2026 | 1.554B |
| June 25, 2026 | 1.526B |
| June 24, 2026 | 1.479B |
| June 23, 2026 | 1.466B |
| June 22, 2026 | 1.446B |
| June 18, 2026 | 1.385B |
| June 17, 2026 | 1.426B |
| June 16, 2026 | 1.332B |
| June 15, 2026 | 1.326B |
| June 12, 2026 | 1.302B |
| June 11, 2026 | 1.328B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| MapLight Therapeutics, Inc. | 206.61M |
| Evommune, Inc. | 316.51M |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Oncolytics Biotech, Inc. | 101.41M |
| Sangamo Therapeutics, Inc. | 50.70M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -241.07M |
| Total Expenses (Quarterly) | 241.07M |
| EPS Diluted (Quarterly) | -2.845 |
| Earnings Yield | -16.78% |
| Normalized Earnings Yield | -16.78 |